HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hemorrhoid, Lice Treatments Join Usual Suspects On FDA Import Alerts

This article was originally published in The Rose Sheet

Executive Summary

"Detention without physical examination" alerts were ordered for the products because evidence exists that they are marketed or promoted as unapproved drugs to consumers in the US.

You may also be interested in...



Coronavirus Slams US Consumer Health Industry Event Schedules, FDA Meetings, Inspections

In addition to postponing NDAC meeting on food handler antiseptic drug products, FDA is suspending most inspections of foreign manufacturing facilities through April. Latest consumer health industry conferences cancelled or postponed are Consumer Healthcare Product Association and Informa Markets events.

Chinese OTC Patch Manufacturer Feels Pain Of US FDA Import Alert, Warning

FDA places Kangdi Medical Devices on import alert and warns it on GMP violations initially noted in 2016. FDA also notes in warning that the Chinese company’s two pain-relief patches are noncompliant with the external analgesics TFM.

Poor Fit For FitTea Evidence, No Free Pass For Testimonials – NAD

NAD advises Fit Products to modify FitTea claims because its formulation is not the same as studies submitted and reminds the firm that testimonials must not contain false claims about products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel